Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020

Basit Öğe Kaydı
dc.contributor.authorNaehrlich, Lutz
dc.contributor.authorOrenti, Annalisa
dc.contributor.authorDunlevy, Fiona
dc.contributor.authorKasmi, Irena
dc.contributor.authorHarutyunyan, Satenik
dc.contributor.authorPfleger, Andreas
dc.contributor.authorKeegan, Svetlana
dc.date.accessioned2024-02-23T14:12:34Z
dc.date.available2024-02-23T14:12:34Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractBackground: Viral infections can cause significant morbidity in cystic fibrosis (CF). The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could therefore have a serious impact on the health of people with CF (pwCF). Methods: We used the 38-country European Cystic Fibrosis Society Patient Registry (ECFSPR) to collect case data about pwCF and SARS-CoV-2 infection. Results: Up to 30 June 2020, 16 countries reported 130 SARS-CoV-2 cases in people with CF, yielding an incidence of 2.70/10 0 0 pwCF. Incidence was higher in lung-transplanted patients (n = 23) versus non transplanted patients (n = 107) (8.43 versus 2.36 cases/10 0 0). Incidence was higher in pwCF versus the age-matched general population in the age groups < 15, 15-24, and 25-49 years (p < 0.001), with similar trends for pwCF with and without lung transplant. Compared to the general population, pwCF (regardless of transplantation status) had significantly higher rates of admission to hospital for all age groups with available data, and higher rates of intensive care, although not statistically significant. Most pwCF recovered (96.2%), however 5 died, of whom 3 were lung transplant recipients. The case fatality rate for pwCF (3.85%, 95% CI: 1.26-8.75) was non-significantly lower than that of the general population (7.46%; p = 0.133). Conclusions: SARS-CoV-2 infection can result in severe illness and death for pwCF, even for younger patients and especially for lung transplant recipients. PwCF should continue to shield from infection and should be prioritized for vaccination. (c) 2021 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )en_US
dc.identifier.doi10.1016/j.jcf.2021.03.017
dc.identifier.endpage577en_US
dc.identifier.issn1569-1993
dc.identifier.issn1873-5010
dc.identifier.issue4en_US
dc.identifier.pmid34016559en_US
dc.identifier.scopus2-s2.0-85110442858en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage566en_US
dc.identifier.urihttps://doi.org/10.1016/j.jcf.2021.03.017
dc.identifier.urihttps://hdl.handle.net/20.500.12452/12113
dc.identifier.volume20en_US
dc.identifier.wosWOS:000688499300004en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofJournal Of Cystic Fibrosisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCystic Fibrosisen_US
dc.subjectCovid-19en_US
dc.subjectSars-Cov-2en_US
dc.subjectEuropeen_US
dc.subjectIncidenceen_US
dc.subjectEpidemiologyen_US
dc.titleIncidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu